Table 1.
Clinical Characteristics of the BOS and Non-BOS Cases from the Study Cohort
| Clinical Variables | BOS (%)N = 63 | Non-BOS (%)N = 883 | P value |
|---|---|---|---|
| Age, median: 48.25, range: 13.0 – 74.5 | 0.474 | ||
| Male: Female Ratio | 1 : 0.6 | 1 : 0.7 | 0.484 |
| Sex Match, Donor—Recipient | |||
| Female—Male | 22 (35) | 230 (26) | 0.395 |
| Female—Female | 13 (21) | 172 (20) | |
| Male—Male | 18 (29) | 291 (33) | |
| Male—Female | 10 (16) | 189 (21) | |
| Race | 71% White | 84% White | 0.014 |
| Disease risk at transplant | |||
| Low | 12 (19) | 130 (15) | 0.623 |
| Intermediate | 26 (41) | 400 (45) | |
| High | 25 (40) | 353 (40) | |
| Donor HLA Status | |||
| Matched/related | 34 (54) | 477 (64) | 0.778 |
| Mismatched/related | 20 (32) | 245 (33) | |
| Unrelated | 1 (2) | 23 (3) | |
| Stem Cell Source | |||
| Bone Marrow | 59(94) | 749 (85) | 0.155 |
| PBSC | 4 (6) | 130 (15) | |
| Others | 0 (0) | 4 (1) | |
| Cytomegalovirus serologic status, recipient – donor | |||
| Negative – Negative | 20 (32) | 262 (30) | 0.320 |
| Negative – Positive | 9 (14) | 109 (12) | |
| Positive – Negative | 12 (19) | 262 (30) | |
| Positive – Positive | 22 (35) | 248 (28) | |
| Conditioning regimens | |||
| Reduced Intensity | 26 (41) | 312 (35) | 0.319 |
| Myeloablative | 37 (59) | 571 (65) | |
| TBI | 9 (56) | 195 (34) | |
| Non-TBI | 28 (44) | 376 (66) | |
| Busulfan-based Conditioning Regimen | 27 (43) | 356 (43) | 0.692 |
| Acute GVHD Grade | |||
| 0/1/2 | 60 (95) | 745 (87) | 0.061 |
| 3 | 3 (5) | 109 (13) | |
| Chronic GVHD | |||
| Positive | 63 (100) | 444 (65) | <0.001 |
| Negative | 0 (0) | 240 (35) | |
| Baseline FEV1 | |||
| ≥ 80% | 47 (75) | 712 (81) | 0.071 |
| 70 – 79% | 10 (16) | 96 (11) | |
| 60 – 69% | 6 (10) | 36 (4) | |
| < 60% | 0 (0) | 23 (3) | |
| Smoking | |||
| Never | 7 (11) | 128 (15) | 0.623 |
| Former | 1 (2) | 37 (4) | |
| Current | 0 (0) | 10 (1) | |
| Prior Interstitial Pneumonitis | 2 (3) | 91 (10) | 0.066 |